Nov 27 (Reuters) - UK speciality pharmaceuticals company ProStrakan Group Plc on Thursday said it gave an exclusive license to Bayer Schering Pharma to develop and market its testosterone replacement gel Tostran in 65 countries for an undisclosed amount.
